Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.
Also in this 8-page issue: Rep. James Greenwood to become president of Biotechnology Industry Association.
Medicare to cut payments for cancer drugs by 2-8%. ASCO estimates total cut in reimbursement at $500 million.
Richard Bloch, advocate for patient information services, dead at 78.
STAR completes enrollment.
NCI forms pediatric central IRB.
Funding opportunities listed.
July issue of Business & Regulatory report (8 additional pages) included.
Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- ASCO & The Conquer Cancer Foundation announce merit awards
- CBER Director Vinay Prasad dared to “say no to drugs”
- By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”
